BTIG analyst Gregory Lewis maintained a Buy rating on Blue Bird (BLBD – Research Report) today and set a price target of $45.00. The company’s ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

BTIG Research has recently reduced Ginkgo Bioworks Holdings Inc (DNA) stock to Sell rating, as announced on May 15, 2024, according to Finviz. Earlier, on May 10, 2024, William Blair had reduced the ...

BTIG maintained a positive stance on Fiserv (NYSE:FI) (NYSE:FISV) shares, with analyst Andrew Harte raising the price target to $240 from the previous $235 while reiterating a Buy rating. The stock, ...

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

This partnership addresses the growing demand among institutional traders for advanced, centralised technology that enables ...

While value offerings are helping improve sales, some franchisees have yet to fully recover their visits and sales comps as ...

Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently ...

BTIG Research has recently reduced MGM Resorts International (MGM) stock to Neutral rating, as announced on February 3, 2025, according to Finviz. Earlier, on July 3, 2024, BTIG Research had initiated ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...